Global
CN
EN
About
Development milestones
Mission&Vision
Founder
Research Achievement
Technology Platforms
Single domain antibody
Five core technology platforms
PIPELINE
BUSINESS PARTNERSHIPS
Product Out-Licensing
Co-Development
investor
Career development
Our Story
Social Recruitment
News
Company News
Media
Contact Us
Company Address
Online Message
×
Home
中文
EN
About
About Novamab
Technology Platforms
PIPELINE
BUSINESS PARTNERSHIPS
Market target layout
Strategic Cooperation
Career development
News
Company News
Media
Contact Us
Our Story
Share the latest information
Our Story
News
Company News
Media
2025-05-13
Novamab to Present Phase IIa Clinical Trial Data of LQ036 at ATS 2025
More
2022-09-13
Novamab Biological announced the appointment of Ms. Huang Jing as the company's chief business officer
More
2022-09-08
Novamab won the nomination award of "Star of the Future" in biomedicine
More
2022-08-22
Celebrate the official commencement of GMP production!
More
2022-07-15
Novamab participated in the development of COVID-19 neutralizing antibody molecular imaging technology, and the research results were published in Research!
More
2022-05-07
The research achievements on COVID-19 by Novamab and Professor Li Henan of Jiangsu University were published in the international journal Analytica Chimica Acta!
More
2022-01-27
The clinical trial of LQ036, the world's first inhaled nanoantibody drug for the treatment of moderate and severe asthma, was approved by CDE!
More
2021-12-31
Dr. Wan Yakun, founder of Novamab, was successfully selected as "Zhangjiang Outstanding Talent in 2021"!
More
2021-11-29
Novamab announced that its LQ036 (recombinant anti-IL-4Ra single-domain antibody aerosol) was accepted by IND!
More
2021-10-18
The fourth anniversary celebration of Novamab was successfully held!
More
2021-10-11
Novamab announced that its anti-IL-4R sdAb LQ036 clinical phase I study completed the first subject administration!
More
总计 53
1
2
3
4
5
6